Anti-HBc positivity is associated with more severe clinical outcomes, such as lower platelet counts, higher bleeding risk and prolonged hospitalization, and may adversely affect prognosis and treatment response in ITP patients. The gene discussed is KRT88P; the disease is autoimmune thrombocytopenic purpura.